Patents by Inventor Lekshmi Reghu Nath

Lekshmi Reghu Nath has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Uttroside B and derivatives thereof as therapeutics for hepatocellular carcinoma
    Patent number: 11738036
    Abstract: The present invention includes Uttroside B compositions and method for the treatment of hepatocellular carcinoma. Chemotherapeutic options for liver cancer are limited and the prognosis of HCC patients remains dismal. Sorafenib, is the only drug currently available for the treatment of hepatocellular carcinoma.
    Type: Grant
    Filed: May 27, 2017
    Date of Patent: August 29, 2023
    Assignee: RAJIV GANDHI CENTRE FOR BIOTECHNOLOGY, AN AUTONOMOUS INSTITUTE UNDER THE DEPARTMENT OF BIOTECHNOLOGY, GOVERNMENT OF INDIA
    Inventors: Ruby John Anto, Lekshmi Reghu Nath
  • Uttroside B and derivatives thereof as therapeutics for hepatocellular carcinoma
    Patent number: 11607422
    Abstract: The present invention includes Uttroside B compositions and method for the treatment of hepatocellular carcinoma. Chemotherapeutic options for liver cancer are limited and the prognosis of HCC patients remains dismal. Sorafenib, is the only drug currently available for the treatment of hepatocellular carcinoma.
    Type: Grant
    Filed: January 29, 2021
    Date of Patent: March 21, 2023
    Assignee: RAJIV GANDHI CENTRE FOR BIOTECHNOLOGY, AN AUTONOMOUS INSTITUTE UNDER THE DEPARTMENT OF BIOTECHNOLOGY. GOVERNMENT OF INDIA
    Inventors: Ruby John Anto, Lekshmi Reghu Nath
  • Uttroside B and Derivatives Thereof as Therapeutics for Hepatocellular Carcinoma
    Publication number: 20210154220
    Abstract: The present invention includes Uttroside B compositions and method for the treatment of hepatocellular carcinoma. Chemotherapeutic options for liver cancer are limited and the prognosis of HCC patients remains dismal. Sorafenib, is the only drug currently available for the treatment of hepatocellular carcinoma.
    Type: Application
    Filed: January 29, 2021
    Publication date: May 27, 2021
    Inventors: Ruby John Anto, Lekshmi Reghu Nath
  • Uttroside B and Derivatives Thereof as Therapeutics for Hepatocellular Carcinoma
    Publication number: 20190160088
    Abstract: The present invention includes Uttroside B compositions and method for the treatment of hepatocellular carcinoma. Chemotherapeutic options for liver cancer are limited and the prognosis of HCC patients remains dismal. Sorafenib, is the only drug currently available for the treatment of hepatocellular carcinoma.
    Type: Application
    Filed: May 27, 2017
    Publication date: May 30, 2019
    Inventors: Ruby John Anto, Lekshmi Reghu Nath